Therapeutic siRNAs/interventions |
Targeted gene |
Delivery |
Diseased
Condition |
Phase |
Status |
Sponsor |
Results/comments |
NCT number |
Ref. |
siG12D-LODER/ Gemcitabine+nab-Paclitaxel |
KRAS-G12D |
Intratumor
placement, Surgical implantation/ LODER polymer |
Pancreatic Cancer |
II |
Recruiting |
Silenseed Ltd |
siG12D-LODERTM consists
of two major parts. The first part is a polymeric matrix which
encapsulates the second part, anti-KRASG12D siRNA. This therapeutic
agent shows prolonged antitumor effect, due to slow release. |
NCT01676259 |
(Golan et al., 2015; Weng et al., 2019) |
siG12D LODER |
KRAS-G12D |
Intratumor placement, Surgical implantation/
LODER polymer |
Pancreatic Cancer |
I |
Completed |
Silenseed Ltd |
KRAS
oncogene mutations (commonly G12D) has been mostly observed in the PDAC,
as a result, stable KRASG12D siRNA drug treatment is promising strategy
to cause apoptosis of such pancreatic tumor cells. |
NCT01188785 |
(Golan et al., 2015) |
KRAS-G12D siRNA |
KRAS-G12D |
i.v. infusion/ Mesenchymal Stromal
Cells-derived Exosomes |
Pancreatic Cancer |
I |
Not yet recruiting |
M.D. Anderson Cancer Center |
In these clinical trial studies, the most
suitable dose and adverse effects of using exosomes derived from
mesenchymal stromal cells for KrasG12D siRNA (iExosomes) delivery in
treating participants with metastatic pancreatic cancer with KrasG12D
mutation has been studied. iExosomes can show higher efficacy in
pancreatic cancer therapy. |
NCT03608631 |
(Das, Musetti, & Huang,
2018; Elahi, Farwell, Nolta, & Anderson, 2019) |
Atu027 & gemcitabine |
PKN3 |
i.v./ cationic lipoplex |
Metastatic
Pancreatic Cancer |
I/II |
Completed |
Silence Therapeutics GmbH |
Atu027, which has great antimetastatic effect, is a siRNA-encapsulated
liposome. This drug can suppress the expression of protein kinase N3
(PKN3) in the vascular endothelium. PKN3 is believed to be a Rho
effector, which mediates the growth of pancreatic cancer cell downstream
of PI3K. It has been shown that gemcitabine and Atu027 combination is
safe for advanced pancreatic cancer therapy. |
NCT01808638 |
(Schultheis
et al., 2018; Strumberg et al., 2012) |
TKM-080301 |
PLK1 |
i.v./ LNP |
Pancreas Cancer with Hepatic Metastasis |
I |
Completed |
National Cancer Institute (NCI) |
TKM-080301 is a
lipid nanoparticle siRNA delivery system. This therapeutic agent can
efficiently suppress polo-like kinase 1 (PLK1) expression. It has been
demonstrated that TKM-080301 has antitumor efficacy for pancreas cancer
with hepatic metastases. |
NCT01437007 |
(Demeure et al.,
2016) |